TOP TIERMARKET NEWSWIRE
News & sentiment

MIRUM PHARMACEUTICAL (MIRM) — News & AI sentiment

MIRUM PHARMACEUTICAL (MIRM) news roundup. 1 story in the last 24 hours, 6 in the past week, 34 over 30 days. Average 24-hour sentiment is 50/100 — neutral (50 is neutral). Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 7 sales totalling $10.8M — net selling of $10.8M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
1
avg sentiment 50/100
7d stories
6
avg sentiment 59.5/100
30d stories
34
avg sentiment 60.8/100
Insider net (90d)
$10.8M
0 buys · 7 sells
Congress (90d)
0
0 buys · 0 sells

MIRM news in the last 24 hours, 7 days, 30 days and 90 days

How much MIRM coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowMIRM storiesAvg AI sentimentRead
Last 24 hours150/100MIRM headlines →
Last 7 days659.5/100MIRM headlines →
Last 30 days3460.8/100MIRM headlines →
Last 90 days7258.5/100MIRM headlines →

Latest stories on MIRM

22h ago
2d ago
2d ago
2d ago
7d ago
7d ago
Oct 21
Oct 15
Stifel raises Mirum Pharmaceuticals stock price target on approvals
Investing.com Analyst Ratings64 · neutralanalyst
Oct 15
Oct 14
At a glance: stocks gapping up premarket
Seeking Alpha58 · neutralgeneral
Oct 14
Oct 13
Oct 13
Oct 13
Oct 12
Oct 12
Oct 12
Oct 12
Raymond James reiterates Strong Buy on Mirum stock after trial data
Investing.com Analyst Ratings64 · neutralanalyst
Oct 12
Oct 12
TD Cowen reiterates Mirum Pharmaceuticals stock Buy rating at $140
Investing.com Analyst Ratings61 · neutralanalyst
Oct 12
Baird reiterates Mirum Pharmaceuticals stock rating on trial success
Investing.com Analyst Ratings63 · neutralanalyst
Oct 12
Oct 12
RBC Capital reiterates Mirum Pharmaceuticals stock rating on trial data
Investing.com Analyst Ratings52 · neutralanalyst
Oct 12
Stifel reiterates Buy on Mirum Pharmaceuticals stock, $136 target
Investing.com Analyst Ratings63 · neutralanalyst
Oct 12
Open MIRM in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →